

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



LUYE PHARMA GROUP LTD.

绿叶制药集团有限公司

(Incorporated in Bermuda with limited liability)

(Stock Code: 02186)

POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 28 MAY 2024

At the annual general meeting (the “**AGM**”) of Luye Pharma Group Ltd. (the “**Company**”) held on 28 May 2024, a poll was demanded by the chairman of the AGM for voting on all the proposed resolutions as set out in the notice of the AGM dated 30 April 2024 (the “**AGM Notice**”).

As at the date of the AGM, the total number of issued shares of the Company was 3,761,670,643 shares of US\$0.02 each, being the total number of shares entitling the shareholders of the Company (the “**Shareholders**”) to attend and vote for or against the resolutions at the AGM. There were no restrictions on any Shareholders casting vote on any of the proposed resolutions at the AGM. No Shareholder was required to attend and vote only against the proposed resolutions at the AGM. None of the Shareholders has stated their intention in the circular of the Company dated 30 April 2024 (the “**Circular**”) to vote against or to abstain from voting on the proposed resolutions at the AGM.

The Company’s Hong Kong share registrar, Computershare Hong Kong Investor Services Limited, was appointed as the scrutineer at the AGM for the purpose of vote-taking.

POLL RESULTS OF AGM

The poll results in respect of the respective resolutions proposed at the AGM were as follow:

Ordinary Resolutions		Number of Votes (%)	
		For	Against
1.	To receive and adopt the audited consolidated financial statements of the Company and the reports of the directors of the Company (the “ Directors ”) and of the auditor of the Company (the “ Auditor ”) for the year ended 31 December 2023.	1,632,155,848 (99.918304%)	1,334,500 (0.081696%)
2.	(a) To re-elect Mr. YANG Rong Bing as an executive Director;	1,630,379,639 (99.809567%)	3,110,709 (0.190433%)
	(b) To re-elect Mr. YUAN Hui Xian as an executive Director;	1,630,376,639 (99.809383%)	3,113,709 (0.190617%)
	(c) To re-elect Dr. LYU Dong as a non-executive Director;	1,077,357,301 (99.647701%)	3,808,939 (0.352299%)
	(d) To re-elect Mr. ZHANG Hua Qiao as an independent non-executive Director;	1,625,869,904 (99.533487%)	7,620,444 (0.466513%)
	(e) To re-elect Mr. CHOY Sze Chung Jojo as an independent non-executive Director; and	1,627,804,735 (99.651935%)	5,685,613 (0.348065%)
	(f) To authorise the board of directors of the Company (the “ Board ”) to fix the remuneration of the Directors.	1,632,984,248 (99.969017%)	506,100 (0.030983%)
3.	To re-appoint Ernst & Young as the Auditor to hold office until the conclusion of the next annual general meeting of the Company and to authorise the Board to fix their remuneration for the year ending 31 December 2024.	1,633,474,857 (99.999052%)	15,491 (0.000948%)
4.	(A) To give a general mandate to the Directors to allot, issue and deal with additional shares and to sell and transfer any treasury shares of the Company (“ Treasury Shares ”) not exceeding 20% of the total number of issued shares of the Company (excluding Treasury Shares, if any) as at the date of passing of this resolution (the “ Issue Mandate ”).	988,941,062 (60.541592%)	644,549,286 (39.458408%)
	(B) To give a general mandate to the Directors to repurchase shares not exceeding 10% of the total number of issued shares of the Company (excluding Treasury Shares, if any) as at the date of passing of this resolution.	1,633,476,648 (99.999161%)	13,700 (0.000839%)
	(C) To extend the Issue Mandate by the number of shares repurchased by the Company.	990,049,362 (60.613726%)	643,325,486 (39.386274%)

SPECIAL RESOLUTION		Number of Votes (%)	
		For	Against
5.	To approve the proposed amendments to the Bye-laws of the Company and to adopt the amended and restated Bye-laws of the Company in substitution for and to the exclusion of the current Bye-laws of the Company.	1,633,346,248 (99.999198%)	13,100 (0.000802%)

Note: Please refer to the AGM Notice for the full text of the resolutions.

As more than 50% of the votes were cast in favour of the ordinary resolutions and not less than 75% of the votes were cast in favour of the special resolution, all resolutions proposed at the AGM were duly passed by way of poll as ordinary resolutions (or as special resolution, as the case may be) by the Shareholders.

All directors of the Company (except for Mr. YUAN Hui Xian and Dr. LYU Dong, who were unable to attend due to other work commitment) attended the AGM.

By order of the Board
LUYE PHARMA GROUP LTD.
Liu Dian Bo
Chairman

Hong Kong, 28 May 2024

As at the date of this announcement, the executive directors of the Company are Mr. LIU Dian Bo, Mr. YANG Rong Bing, Mr. YUAN Hui Xian and Ms. ZHU Yuan Yuan; the non-executive directors of the Company are Mr. SONG Rui Lin and Dr. LYU Dong; and the independent non-executive directors of the Company are Mr. ZHANG Hua Qiao, Professor LO Yuk Lam, Mr. LEUNG Man Kit, Mr. CHOY Sze Chung Jojo and Ms. XIA Lian.